Key Points
- Elanco insider Timothy Bettington sold 4,350 shares at an average price of $23.00, generating $100,050. The transaction reduced his ownership by 3.04% and was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Elanco recently reported stronger-than-expected quarterly results, with $0.34 in EPS versus the $0.27 consensus estimate and revenue of $1.37 billion, up 10.2% year over year.
- Analysts maintain a generally positive outlook, with the stock receiving a “Moderate Buy” consensus rating and an average price target of $29.91 versus its recent price near $23.50. Institutional investors own 97.48% of the company.
Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) insider Timothy Bettington sold 4,350 shares of the business's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $23.00, for a total transaction of $100,050.00. Following the transaction, the insider owned 138,911 shares in the company, valued at $3,194,953. The trade was a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Elanco Animal Health Stock Down 0.2%
Shares of NYSE ELAN opened at $23.50 on Tuesday. The stock has a market cap of $11.74 billion, a PE ratio of -57.31, a P/E/G ratio of 1.68 and a beta of 1.70. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a 12-month low of $19.40 and a 12-month high of $27.98. The company has a 50-day moving average of $23.25 and a 200 day moving average of $23.58.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping analysts' consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same period last year, the company posted $0.26 EPS. The business's revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, sell-side analysts predict that Elanco Animal Health Incorporated will post 1.13 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on ELAN. UBS Group lifted their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Morgan Stanley boosted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 22nd. KeyCorp reiterated an "overweight" rating on shares of Elanco Animal Health in a report on Wednesday, September 30th. Piper Sandler reissued an "overweight" rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Finally, The Goldman Sachs Group initiated coverage on shares of Elanco Animal Health in a research note on Friday. They issued a "buy" rating and a $32.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $29.91.
View Our Latest Research Report on Elanco Animal Health
Institutional Investors Weigh In On Elanco Animal Health
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Elanco Animal Health in the 2nd quarter valued at $1,202,198,000. Primecap Management Co. CA purchased a new position in shares of Elanco Animal Health during the 2nd quarter worth $1,118,402,000. State Street Corp grew its holdings in shares of Elanco Animal Health by 4.7% during the 2nd quarter. State Street Corp now owns 16,063,046 shares of the company's stock worth $395,312,000 after purchasing an additional 726,567 shares during the period. The Manufacturers Life Insurance Company purchased a new position in shares of Elanco Animal Health during the 2nd quarter worth $205,636,000. Finally, Sei Investments Co. increased its position in shares of Elanco Animal Health by 737.5% during the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company's stock worth $135,214,000 after purchasing an additional 4,975,721 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.
Elanco Animal Health Company Profile
(
Get Free Report)
Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.
The company's products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.
Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
